Stephens Inc. AR Buys 44,270 Shares of Novo Nordisk A/S (NYSE:NVO)

Stephens Inc. AR raised its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 42.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 147,688 shares of the company's stock after purchasing an additional 44,270 shares during the period. Stephens Inc. AR's holdings in Novo Nordisk A/S were worth $10,255,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. GQG Partners LLC lifted its stake in shares of Novo Nordisk A/S by 74.7% in the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock valued at $1,117,790,000 after acquiring an additional 5,556,460 shares during the last quarter. Loomis Sayles & Co. L P increased its stake in Novo Nordisk A/S by 34.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock worth $995,397,000 after purchasing an additional 2,947,771 shares during the period. Nuveen Asset Management LLC lifted its position in Novo Nordisk A/S by 73.2% in the fourth quarter. Nuveen Asset Management LLC now owns 6,244,931 shares of the company's stock valued at $537,189,000 after purchasing an additional 2,639,693 shares during the last quarter. Two Sigma Investments LP bought a new stake in Novo Nordisk A/S in the fourth quarter valued at approximately $158,657,000. Finally, Clearbridge Investments LLC boosted its stake in shares of Novo Nordisk A/S by 59.8% during the fourth quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company's stock valued at $368,451,000 after purchasing an additional 1,602,549 shares during the period. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Down 0.0%

Shares of NYSE:NVO traded down $0.02 during midday trading on Monday, reaching $68.92. The company's stock had a trading volume of 6,011,996 shares, compared to its average volume of 9,245,241. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. The firm has a 50 day moving average of $70.35 and a 200-day moving average of $74.91. The firm has a market capitalization of $307.71 billion, a P/E ratio of 20.39, a PEG ratio of 1.33 and a beta of 0.64. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $143.49.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts' consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The business had revenue of $11.87 billion for the quarter. On average, research analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analyst Ratings Changes

NVO has been the subject of a number of recent analyst reports. BMO Capital Markets reiterated a "market perform" rating and set a $64.00 price target (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Wall Street Zen upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Guggenheim cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Finally, BNP Paribas began coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They set an "underperform" rating on the stock. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S has a consensus rating of "Hold" and a consensus price target of $112.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.